Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure

Donatella Del Sindaco, Giovanni Pulignano, Giovanni Cioffi, Luigi Tarantini, Andrea Di Lenarda, Stefania De Feo, Cristina Opasich, Giovanni Minardi, Ezio Giovannini, Francesco Leggio

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

OBJECTIVE: β-Blockers are often cautiously prescribed to older heart failure diabetics because of the paucity of published data and their perceived unfavourable effects on glucose metabolism, in spite of the evidence of their effectiveness and safety in middle-aged diabetic patients. The aim of this study was to compare the safety, tolerability and efficacy of long-term administration of carvedilol in a group of elderly patients with chronic heart failure, with and without concomitant diabetes. METHODS: Two hundred and fifty-two patients aged ≥70 years with heart failure and left ventricular ejection fraction ≤40% were followed in specialised heart failure clinics. Diabetes was present in 29.7%. Carvedilol was associated with conventional optimised treatment in 64% of diabetics and 65% of non-diabetics (P = NS). RESULTS: At baseline, diabetics presented with a longer duration of symptoms, higher Charlson comorbidity index, more frequent renal dysfunction and smaller left ventricular volumes than non-diabetics. New York Heart Association functional class and ejection fraction were similar in the two groups. At 1-year follow-up, tolerability (93.7 vs. 92.2%) and mean daily dose (24 ± 17 vs. 23 ± 14 mg/day) of carvedilol were similar in diabetics and non-diabetics. No worsening of fasting glucose, glycosylated haemoglobin and creatinine levels as well as the incidence of deaths and hospitalisations was observed in diabetics treated with carvedilol. Similar improvements in New York Heart Association class and mitral regurgitation severity were observed in diabetic and non-diabetic patients taking carvedilol. Ejection fraction showed a significant improvement, more pronounced in non-diabetics than in diabetics (+10 vs. +7 points; improvement of at least 10 points: 15 vs. 36%, P = 0.03). CONCLUSIONS: Similarly to younger ones, also in older patients, diabetes does not negatively influence the safety, tolerability and efficacy of carvedilol. However, diabetes remains a strong prognostic factor limiting the reversibility of left ventricular systolic dysfunction and the effect of treatment on subsequent outcome.

Original languageEnglish
Pages (from-to)675-682
Number of pages8
JournalJournal of Cardiovascular Medicine
Volume8
Issue number9
DOIs
Publication statusPublished - Sep 2007

Fingerprint

Heart Failure
Safety
Left Ventricular Dysfunction
Glucose
Glycosylated Hemoglobin A
Mitral Valve Insufficiency
Stroke Volume
carvedilol
Comorbidity
Fasting
Creatinine
Hospitalization
Kidney
Incidence
Therapeutics

Keywords

  • Carvedilol
  • Diabetes mellitus
  • Elderly
  • Ventricular remodelling

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Del Sindaco, D., Pulignano, G., Cioffi, G., Tarantini, L., Di Lenarda, A., De Feo, S., ... Leggio, F. (2007). Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. Journal of Cardiovascular Medicine, 8(9), 675-682. https://doi.org/10.2459/01.JCM.0000285316.71057.26

Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. / Del Sindaco, Donatella; Pulignano, Giovanni; Cioffi, Giovanni; Tarantini, Luigi; Di Lenarda, Andrea; De Feo, Stefania; Opasich, Cristina; Minardi, Giovanni; Giovannini, Ezio; Leggio, Francesco.

In: Journal of Cardiovascular Medicine, Vol. 8, No. 9, 09.2007, p. 675-682.

Research output: Contribution to journalArticle

Del Sindaco, D, Pulignano, G, Cioffi, G, Tarantini, L, Di Lenarda, A, De Feo, S, Opasich, C, Minardi, G, Giovannini, E & Leggio, F 2007, 'Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure', Journal of Cardiovascular Medicine, vol. 8, no. 9, pp. 675-682. https://doi.org/10.2459/01.JCM.0000285316.71057.26
Del Sindaco, Donatella ; Pulignano, Giovanni ; Cioffi, Giovanni ; Tarantini, Luigi ; Di Lenarda, Andrea ; De Feo, Stefania ; Opasich, Cristina ; Minardi, Giovanni ; Giovannini, Ezio ; Leggio, Francesco. / Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure. In: Journal of Cardiovascular Medicine. 2007 ; Vol. 8, No. 9. pp. 675-682.
@article{0b2b8223e37a4fdf8834540e9454d6b0,
title = "Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure",
abstract = "OBJECTIVE: β-Blockers are often cautiously prescribed to older heart failure diabetics because of the paucity of published data and their perceived unfavourable effects on glucose metabolism, in spite of the evidence of their effectiveness and safety in middle-aged diabetic patients. The aim of this study was to compare the safety, tolerability and efficacy of long-term administration of carvedilol in a group of elderly patients with chronic heart failure, with and without concomitant diabetes. METHODS: Two hundred and fifty-two patients aged ≥70 years with heart failure and left ventricular ejection fraction ≤40{\%} were followed in specialised heart failure clinics. Diabetes was present in 29.7{\%}. Carvedilol was associated with conventional optimised treatment in 64{\%} of diabetics and 65{\%} of non-diabetics (P = NS). RESULTS: At baseline, diabetics presented with a longer duration of symptoms, higher Charlson comorbidity index, more frequent renal dysfunction and smaller left ventricular volumes than non-diabetics. New York Heart Association functional class and ejection fraction were similar in the two groups. At 1-year follow-up, tolerability (93.7 vs. 92.2{\%}) and mean daily dose (24 ± 17 vs. 23 ± 14 mg/day) of carvedilol were similar in diabetics and non-diabetics. No worsening of fasting glucose, glycosylated haemoglobin and creatinine levels as well as the incidence of deaths and hospitalisations was observed in diabetics treated with carvedilol. Similar improvements in New York Heart Association class and mitral regurgitation severity were observed in diabetic and non-diabetic patients taking carvedilol. Ejection fraction showed a significant improvement, more pronounced in non-diabetics than in diabetics (+10 vs. +7 points; improvement of at least 10 points: 15 vs. 36{\%}, P = 0.03). CONCLUSIONS: Similarly to younger ones, also in older patients, diabetes does not negatively influence the safety, tolerability and efficacy of carvedilol. However, diabetes remains a strong prognostic factor limiting the reversibility of left ventricular systolic dysfunction and the effect of treatment on subsequent outcome.",
keywords = "Carvedilol, Diabetes mellitus, Elderly, Ventricular remodelling",
author = "{Del Sindaco}, Donatella and Giovanni Pulignano and Giovanni Cioffi and Luigi Tarantini and {Di Lenarda}, Andrea and {De Feo}, Stefania and Cristina Opasich and Giovanni Minardi and Ezio Giovannini and Francesco Leggio",
year = "2007",
month = "9",
doi = "10.2459/01.JCM.0000285316.71057.26",
language = "English",
volume = "8",
pages = "675--682",
journal = "Journal of Cardiovascular Medicine",
issn = "1558-2027",
publisher = "Lippincott Williams and Wilkins",
number = "9",

}

TY - JOUR

T1 - Safety and efficacy of carvedilol in very elderly diabetic patients with heart failure

AU - Del Sindaco, Donatella

AU - Pulignano, Giovanni

AU - Cioffi, Giovanni

AU - Tarantini, Luigi

AU - Di Lenarda, Andrea

AU - De Feo, Stefania

AU - Opasich, Cristina

AU - Minardi, Giovanni

AU - Giovannini, Ezio

AU - Leggio, Francesco

PY - 2007/9

Y1 - 2007/9

N2 - OBJECTIVE: β-Blockers are often cautiously prescribed to older heart failure diabetics because of the paucity of published data and their perceived unfavourable effects on glucose metabolism, in spite of the evidence of their effectiveness and safety in middle-aged diabetic patients. The aim of this study was to compare the safety, tolerability and efficacy of long-term administration of carvedilol in a group of elderly patients with chronic heart failure, with and without concomitant diabetes. METHODS: Two hundred and fifty-two patients aged ≥70 years with heart failure and left ventricular ejection fraction ≤40% were followed in specialised heart failure clinics. Diabetes was present in 29.7%. Carvedilol was associated with conventional optimised treatment in 64% of diabetics and 65% of non-diabetics (P = NS). RESULTS: At baseline, diabetics presented with a longer duration of symptoms, higher Charlson comorbidity index, more frequent renal dysfunction and smaller left ventricular volumes than non-diabetics. New York Heart Association functional class and ejection fraction were similar in the two groups. At 1-year follow-up, tolerability (93.7 vs. 92.2%) and mean daily dose (24 ± 17 vs. 23 ± 14 mg/day) of carvedilol were similar in diabetics and non-diabetics. No worsening of fasting glucose, glycosylated haemoglobin and creatinine levels as well as the incidence of deaths and hospitalisations was observed in diabetics treated with carvedilol. Similar improvements in New York Heart Association class and mitral regurgitation severity were observed in diabetic and non-diabetic patients taking carvedilol. Ejection fraction showed a significant improvement, more pronounced in non-diabetics than in diabetics (+10 vs. +7 points; improvement of at least 10 points: 15 vs. 36%, P = 0.03). CONCLUSIONS: Similarly to younger ones, also in older patients, diabetes does not negatively influence the safety, tolerability and efficacy of carvedilol. However, diabetes remains a strong prognostic factor limiting the reversibility of left ventricular systolic dysfunction and the effect of treatment on subsequent outcome.

AB - OBJECTIVE: β-Blockers are often cautiously prescribed to older heart failure diabetics because of the paucity of published data and their perceived unfavourable effects on glucose metabolism, in spite of the evidence of their effectiveness and safety in middle-aged diabetic patients. The aim of this study was to compare the safety, tolerability and efficacy of long-term administration of carvedilol in a group of elderly patients with chronic heart failure, with and without concomitant diabetes. METHODS: Two hundred and fifty-two patients aged ≥70 years with heart failure and left ventricular ejection fraction ≤40% were followed in specialised heart failure clinics. Diabetes was present in 29.7%. Carvedilol was associated with conventional optimised treatment in 64% of diabetics and 65% of non-diabetics (P = NS). RESULTS: At baseline, diabetics presented with a longer duration of symptoms, higher Charlson comorbidity index, more frequent renal dysfunction and smaller left ventricular volumes than non-diabetics. New York Heart Association functional class and ejection fraction were similar in the two groups. At 1-year follow-up, tolerability (93.7 vs. 92.2%) and mean daily dose (24 ± 17 vs. 23 ± 14 mg/day) of carvedilol were similar in diabetics and non-diabetics. No worsening of fasting glucose, glycosylated haemoglobin and creatinine levels as well as the incidence of deaths and hospitalisations was observed in diabetics treated with carvedilol. Similar improvements in New York Heart Association class and mitral regurgitation severity were observed in diabetic and non-diabetic patients taking carvedilol. Ejection fraction showed a significant improvement, more pronounced in non-diabetics than in diabetics (+10 vs. +7 points; improvement of at least 10 points: 15 vs. 36%, P = 0.03). CONCLUSIONS: Similarly to younger ones, also in older patients, diabetes does not negatively influence the safety, tolerability and efficacy of carvedilol. However, diabetes remains a strong prognostic factor limiting the reversibility of left ventricular systolic dysfunction and the effect of treatment on subsequent outcome.

KW - Carvedilol

KW - Diabetes mellitus

KW - Elderly

KW - Ventricular remodelling

UR - http://www.scopus.com/inward/record.url?scp=34548049802&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34548049802&partnerID=8YFLogxK

U2 - 10.2459/01.JCM.0000285316.71057.26

DO - 10.2459/01.JCM.0000285316.71057.26

M3 - Article

C2 - 17700396

AN - SCOPUS:34548049802

VL - 8

SP - 675

EP - 682

JO - Journal of Cardiovascular Medicine

JF - Journal of Cardiovascular Medicine

SN - 1558-2027

IS - 9

ER -